Roche NimbleGen Announces Frank Pitzer as New CEO
News Mar 26, 2010
Roche NimbleGen has announced that Frank Pitzer has been appointed as CEO. Dr. Pitzer’s extensive background and experience of over eight years at Roche will be instrumental in guiding the company through its next stage of growth.
With his successful track record in several key management positions within Roche Diagnostics, he brings a wealth of organizational, commercial, and relevant operating experience in key areas impacting the genomics and life science industry.
Dr. Pitzer most recently served as Head of Divisional Quality and Regulatory Affairs reporting directly to the CEO of Roche Diagnostics and was also an active member of the Diagnostics Executive Committee (DEC). In addition to his extensive management experience and background at Roche, Dr. Pitzer brings a broad scientific perspective having earned a PhD in Biology from Max Planck Institute for Biochemistry.
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE